Literature DB >> 14572797

Red blood cells promote survival and cell cycle progression of human peripheral blood T cells independently of CD58/LFA-3 and heme compounds.

Ana Mafalda Fonseca1, Carlos Filipe Pereira, Graça Porto, Fernando A Arosa.   

Abstract

Red blood cells (RBC) are known to modulate T cell proliferation and function possibly through downregulation of oxidative stress. By examining parameters of activation, division, and cell death in vitro, we show evidence that the increase in survival afforded by RBC is due to the maintenance of the proliferative capacity of the activated T cells. We also show that the CD3+CD8+ T cell subset was preferentially expanded and rescued from apoptosis both in bulk peripheral blood lymphocyte cultures and with highly purified CD8+ T cells. The ability of RBC to induce survival of dividing T cells was not affected by blocking the CD58/CD2 interaction. Moreover, addition of hemoglobin, heme or protoporphyrin IX to cultures of activated T cells did not reproduce the effect of intact RBC. Considering that RBC circulate throughout the body, they could play a biological role in the modulation of T cell differentiation and survival in places of active cell division. Neither CD58 nor the heme compounds studied seem to play a direct relevant role in the modulation of T cell survival.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14572797     DOI: 10.1016/s0008-8749(03)00170-9

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  10 in total

1.  Red blood cells carry out T cell growth and survival bioactivities that are sensitive to cyclosporine A.

Authors:  Ricardo F Antunes; Cláudia Brandão; Gonçalo Carvalho; Cristina Girão; Fernando A Arosa
Journal:  Cell Mol Life Sci       Date:  2009-10       Impact factor: 9.261

Review 2.  Is there a direct role for erythrocytes in the immune response?

Authors:  Davinia Morera; Simon A MacKenzie
Journal:  Vet Res       Date:  2011-07-29       Impact factor: 3.683

3.  Influence of different ex vivo cell culture methods on the proliferation and anti-tumor activity of cytokine-induced killer cells from gastric cancer patients.

Authors:  Bin Shi; Aixia Sun; Xiaorui Zhang
Journal:  Onco Targets Ther       Date:  2018-05-08       Impact factor: 4.147

4.  Red blood cells exposed to cancer cells in culture have altered cytokine profiles and immune function.

Authors:  Elisabeth Karsten; Edmond Breen; Sharon A McCracken; Stephen Clarke; Benjamin R Herbert
Journal:  Sci Rep       Date:  2020-05-07       Impact factor: 4.379

Review 5.  Coronavirus disease 2019 (COVID-19), human erythrocytes and the PKC-alpha/-beta inhibitor chelerythrine -possible therapeutic implication.

Authors:  Mehrdad Ghashghaeinia; Peter Dreischer; Thomas Wieder; Martin Köberle
Journal:  Cell Cycle       Date:  2020-12-11       Impact factor: 4.534

Review 6.  How Do Inflammatory Mediators, Immune Response and Air Pollution Contribute to COVID-19 Disease Severity? A Lesson to Learn.

Authors:  Cinzia Signorini; Patrizia Pignatti; Teresa Coccini
Journal:  Life (Basel)       Date:  2021-02-25

7.  The Antibacterial Activity of Erythrocytes From Goose (Anser domesticus) Can Be Associated With Phagocytosis and Respiratory Burst Generation.

Authors:  Youcheng Yang; Jiajun Chen; Linqing Lu; Zizheng Xu; Feng Li; Minxuan Yang; Jun Li; Li Lin; Zhendong Qin
Journal:  Front Immunol       Date:  2022-01-13       Impact factor: 7.561

Review 8.  Erythrocyte degradation, metabolism, secretion, and communication with immune cells in the blood during sepsis: A review.

Authors:  Chih-Yu Chan; Ching-Feng Cheng; Hao-Ai Shui; Hui-Chen Ku; Wen-Lin Su
Journal:  Tzu Chi Med J       Date:  2021-10-05

9.  Erythrocyte and blood antibacterial defense.

Authors:  Hayk Minasyan
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2014-05-21

10.  Impact of heme on specific antibody production in mice: promotive, inhibitive or null outcome is determined by its concentration.

Authors:  Guofu Li; Haiyan Xue; Zeng Fan; Yun Bai
Journal:  Heliyon       Date:  2017-05-16
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.